Global Alzheimer’s Drug Market Size is expected to rise from USD 2839 million in 2016, to attain USD 5069 million by 2025. The Market Size Expands at 6.7% CAGR By 2025.
Table of Contents
Introduction
Alzheimer’s is a type of neurodegenerative disease that affects a part of the brain that helps control the language, memory, and thought processes of the person, and over time can hamper a person’s ability to perform their day-to-day activities. It is a progressive disease of the brain that leads to the loss of memory and various cognitive functions. As Alzheimer’s is a progressive disease, its symptoms will gradually worsen over a period of time. Alzheimer’s is the most common type of dementia and accounts for almost 60%-80% of all dementia cases. Currently, this disease does not have a cure but can be kept under control through regular treatments with appropriate drugs. However, regular research and development activities are taking place in the field of Alzheimer’s drugs in order to introduce new drug candidates that have the potential to prevent or slow down the progression of Alzheimer’s disease. Some of the latest introductions of Alzheimer’s drugs include passive immunotherapies, aducanumab, crenezumab which have the ability to take over the market in the coming seven years. Alzheimer’s treatment is a high-risk, high-reward market. The global Alzheimer’s drug market is anticipated to experience a rapid growth rate throughout the forecast period in terms of revenue (USD Million).
Report Description
The market for Alzheimer’s drugs has been covered under the scope of this report. Alzheimer’s disease is one type of neurodegenerative disease of the brain that leads to cognitive function and memory loss. The Alzheimer’s drug market is expected to witness strong growth during the forecast period. In addition, the increase in awareness programmes regarding this disease and the rise in the number of cases of Alzheimer’s disease are the major factors contributing to this growth. The global Alzheimer’s drug market has been segmented on the basis of:
- Drug class
- Distribution channels, and
- Regions
It also provides a cross sectional study of the global Alzheimer’s drug market across broad regional segments such as North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America under its scope. Various Alzheimer’s vendors, which include H Lundbeck A/S, Ono Pharmaceutical, and Eisai Co Ltd., among others, are continuously focusing on the development of next-generation Alzheimer’s drugs. This in turn is anticipated to have further contributed to the growth of the global Alzheimer’s drug market in the future. Moreover, some of the latest introductions of Alzheimer’s drugs, which include passive immunotherapy, aducanumab, crenezumab, and aducanumab, have the ability to uptake the market during the forecast period. Trends show that in the last couple of years, Biogen, one of the state’s most valuable public biotech companies, has invested heavily in Alzheimer’s drug research and development. Furthermore, the Alzheimer’s disease drug market is expected to grow at a potential rate due to the high prevalence of Alzheimer’s disease, which will be followed by increased coverage of Alzheimer’s disease medical treatment. All the above factors are expected to drive the demand for Alzheimer’s drugs worldwide.
Report Highlights
- Impeccable insights related to relevant segment of the market.
- In depth analysis of key trends of the market.
- In-depth analysis of the competitive landscape and competitor behavior in the market.
- Major push factors that will influence the growth of the market.
- Growth potential in different segments of the market till 2025.
- Key strategies executed by the market leaders to maintain growth in the market.
- Major restrictive factors of the market.
- Ways to generate new revenue.
- Free customization with maximum flexibility limit.
Scope of the Report
A complete analysis of market dynamics, which includes the market drivers, restraints, and opportunities, is included within the scope of the report. Market dynamics for the different drug classes and distribution channels have been covered separately under the purview of the report. Additionally, the country-level trend for each region has also been covered under the scope of the report. Thus, this report provides an exhaustive study of the global Alzheimer’s drug market and also provides a forecast of the market for the period from 2017 to 2025.
Market Dynamics
The rising prevalence of Alzheimer’s diseases across the globe, along with increasing awareness about the treatment of Alzheimer’s, is one of the most important factors anticipated to drive the market for Alzheimer’s drugs throughout the forecast period from 2017 to 2025. Several neurodegenerative diseases have become increasingly prevalent in developing countries, especially among elderly people (age above 65) owing to changes in lifestyle and constant tension that lead to brain shrinkage and localised loss of neurons. This in turn leads to constant support from the government to develop drugs that can control the disease. In addition, the currently available Alzheimer’s drugs in the market have reached their maturity and the patents of the leading drugs are either close to expiry or have expired. Thus, the current unmet need is anticipated to create a huge opportunity for various Alzheimer’s drug manufacturers in the coming years.
However, the high price of these advanced drugs is anticipated to deter their acceptance rate in various developing countries across the globe.
High-level Analyses Covered in the Report
Under the scope of the report on global Alzheimer’s drug market, several high-level analyses have been covered. This includes:
- The product-market trend analysis
- Product life-cycle analysis
- Porter’s five forces analysis, and
- Market attractiveness analysis
Key trends analysis discusses the current and upcoming trends in this market. Product life-cycle analysis analyses the current life-cycle stage of the product in the five wide geographic regions, such as whether the product is approaching maturity in a region or whether it is a new entrant, etc. Porter’s five forces analysis provides insights into the competitive scenario with regards to new entrants, substitutes, buyers, and suppliers. To provide a detailed insight into the global Alzheimer’s drug market, attractive analysis has been provided in the report. The market attractiveness analysis details the investment attractiveness by drug class, by distribution channel, and by geography.
The Competitive Profiling
The competitive profiling of the key players in the global Alzheimer’s drug market and their business segments has been exhaustively covered under the purview of the study. Moreover, key business strategies adopted by the leading players in the market have also been covered under the scope of the report.
Leading Companies in the Alzheimer’s Drug Market
The global Alzheimer’s drug market is characterized by the presence of various large and small vendors across the globe. Some of the major manufactures of Alzheimer’s drug includes:
- H Lundbeck A/S (Denmark)
- Ono Pharmaceutical (Japan), Eisai Co Ltd. (Japan), and
- Johnson & Johnson (The U.S) among others.
Segmentation Overview
For the purpose of providing an In-depth analysis reading the demand of Alzheimer’s drug across different geographical regions including North America, Europe, Asia-Pacific, South America and Middle East and Africa, the market has been segmented based on drug class and distribution channel.
By Drug Class
Depending on the chemical structure of the medicine, by drug class, the market has been classified into cholinergic, memantine and combined drugs among others.
- Cholinergic
- Memantine
- Combined Drugs
- Others
By Distribution Channel
Based on various channels via which Alzheimer’s drug reaches to the end consumers, the market has been classified into hospital pharmacy, retail pharmacy and online stores. In many cases, sales representative of the company also delivers the drugs directly to the end customers. But this has not been considered within our scope of research.
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, CIS + Scandinavia and Rest of Europe)
- Asia-Pacific (China, Japan, Taiwan, South Korea and Rest of Asia-Pacific)
- Middle East and Africa (Israel, South Africa and Rest of Middle East and Africa)
- South America (Brazil, Mexico and Rest of South America)
Regional Outlook
Geographically, North America is projected to dominate the market throughout the forecast period in terms of revenue generation. Higher Alzheimer’s disease penetration in this region, coupled with the wide concentration of global players in this region, is the primary factor behind this region’s large market share and stable growth rate. On the flip side, owing to the rising number of geriatrics in the population, Europe is expected to have immense growth potential in the coming eight years.
The latest news from the industry straight to your inbox.
Join 2,000+ subscribers for exclusive access to our monthly newsletter with market research data, industry news.
